246 related articles for article (PubMed ID: 25062695)
1. Sialyllactose ameliorates myopathic phenotypes in symptomatic GNE myopathy model mice.
Yonekawa T; Malicdan MC; Cho A; Hayashi YK; Nonaka I; Mine T; Yamamoto T; Nishino I; Noguchi S
Brain; 2014 Oct; 137(Pt 10):2670-9. PubMed ID: 25062695
[TBL] [Abstract][Full Text] [Related]
2. [Animal model of distal myopathy with rimmed vacuoles/hereditary inclusion body myopathy and preclinical trial with sugar compounds].
Noguchi S; Malicdan MC; Nishino I
Brain Nerve; 2010 Jun; 62(6):601-7. PubMed ID: 20548120
[TBL] [Abstract][Full Text] [Related]
3. A Gne knockout mouse expressing human GNE D176V mutation develops features similar to distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy.
Malicdan MC; Noguchi S; Nonaka I; Hayashi YK; Nishino I
Hum Mol Genet; 2007 Nov; 16(22):2669-82. PubMed ID: 17704511
[TBL] [Abstract][Full Text] [Related]
4. Peracetylated N-acetylmannosamine, a synthetic sugar molecule, efficiently rescues muscle phenotype and biochemical defects in mouse model of sialic acid-deficient myopathy.
Malicdan MC; Noguchi S; Tokutomi T; Goto Y; Nonaka I; Hayashi YK; Nishino I
J Biol Chem; 2012 Jan; 287(4):2689-705. PubMed ID: 22157763
[TBL] [Abstract][Full Text] [Related]
5. [Development of therapy for distal myopathy with rimmed vacuoles].
Nishino I; Malicdan MC; Noguchi S
Rinsho Shinkeigaku; 2009 Nov; 49(11):852-5. PubMed ID: 20030229
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and clinical efficacy of 6'-sialyllactose in patients with GNE myopathy: Randomized pilot trial.
Park YE; Park E; Choi J; Go H; Park DB; Kim MY; Sung NJ; Kim L; Shin JH
Biomed Pharmacother; 2023 Dec; 168():115689. PubMed ID: 37852099
[TBL] [Abstract][Full Text] [Related]
7. A Gne knockout mouse expressing human V572L mutation develops features similar to distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy.
Malicdan MC; Noguchi S; Nonaka I; Hayashi YK; Nishino I
Hum Mol Genet; 2007 Jan; 16(2):115-28. PubMed ID: 17164266
[TBL] [Abstract][Full Text] [Related]
8. Increased amyloid β-peptide uptake in skeletal muscle is induced by hyposialylation and may account for apoptosis in GNE myopathy.
Bosch-Morató M; Iriondo C; Guivernau B; Valls-Comamala V; Vidal N; Olivé M; Querfurth H; Muñoz FJ
Oncotarget; 2016 Mar; 7(12):13354-71. PubMed ID: 26968811
[TBL] [Abstract][Full Text] [Related]
9. [Sialic acid supplementation therapy for distal myopathy with rimmed vacuoles (GNE myopathy)].
Nishino I; Noguchi S
Rinsho Shinkeigaku; 2012; 52(11):1210-2. PubMed ID: 23196566
[TBL] [Abstract][Full Text] [Related]
10. [Sialic Acid supplementation therapy for distal myopathy with rimmed vacuoles].
Nishino I; Noguchi S
Brain Nerve; 2012 Mar; 64(3):255-61. PubMed ID: 22402719
[TBL] [Abstract][Full Text] [Related]
11. GNE myopathy: from clinics and genetics to pathology and research strategies.
Pogoryelova O; González Coraspe JA; Nikolenko N; Lochmüller H; Roos A
Orphanet J Rare Dis; 2018 May; 13(1):70. PubMed ID: 29720219
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model.
Malicdan MC; Noguchi S; Hayashi YK; Nonaka I; Nishino I
Nat Med; 2009 Jun; 15(6):690-5. PubMed ID: 19448634
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathomechanism of distal myopathy with rimmed vacuoles.
Nishino I; Malicdan MC; Murayama K; Nonaka I; Hayashi YK; Noguchi S
Acta Myol; 2005 Oct; 24(2):80-3. PubMed ID: 16550921
[TBL] [Abstract][Full Text] [Related]
14. Autophagy in a mouse model of distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy.
Malicdan MC; Noguchi S; Nishino I
Autophagy; 2007; 3(4):396-8. PubMed ID: 17471014
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of Aceneuramic Acid for Distal Myopathy with Rimmed Vacuoles].
Aoki M; Izumi R; Suzuki N
Brain Nerve; 2023 Oct; 75(10):1149-1154. PubMed ID: 37849366
[TBL] [Abstract][Full Text] [Related]
16. [Sialic Acid Replacement Therapy for Distal Myopathy with Rimmed Vacuoles].
Mori-Yoshimura M; Nishino I
Brain Nerve; 2015 Sep; 67(9):1115-23. PubMed ID: 26329152
[TBL] [Abstract][Full Text] [Related]
17. Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathy.
Xu X; Wang AQ; Latham LL; Celeste F; Ciccone C; Malicdan MC; Goldspiel B; Terse P; Cradock J; Yang N; Yorke S; McKew JC; Gahl WA; Huizing M; Carrillo N
Mol Genet Metab; 2017 Sep; 122(1-2):126-134. PubMed ID: 28641925
[TBL] [Abstract][Full Text] [Related]
18. Sialic acid deficiency is associated with oxidative stress leading to muscle atrophy and weakness in GNE myopathy.
Cho A; Christine M; Malicdan V; Miyakawa M; Nonaka I; Nishino I; Noguchi S
Hum Mol Genet; 2017 Aug; 26(16):3081-3093. PubMed ID: 28505249
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic development for GNE myopathy.].
Suzuki N; Izumi R; Kato M; Warita H; Aoki M
Clin Calcium; 2017; 27(3):429-434. PubMed ID: 28232658
[TBL] [Abstract][Full Text] [Related]
20. [GNE myopathy].
Urtizberea JA; Béhin A
Med Sci (Paris); 2015 Nov; 31 Spec No 3():20-7. PubMed ID: 26546927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
